PON2 and chronic myelogenous leukemia, BCR-ABL1 positive: As reported in previous studies, PON2 upregulation was found in cohorts of pediatric ALL patients with a poor prognosis and in patients with CML resistant to targeted imatinib-based therapy [33,34,35].